The Google and Johnson & Johnson-backed genomic testing service is seeking $150m in a series E round that follows its establishment of a therapeutics group.
23andMe, the US-based DNA testing service backed by several corporate investors, has raised $79.1m as part of a series E round that could reach $150m, according to a regulatory filing on Thursday.
Founded in 2006, 23andMe offers customers a kit that enables them to test their own DNA, in the process researching their ancestry, genealogy and inherited genetic traits. Users provide a saliva sample through the kit and after a few weeks are able to access the results online.
23andMe…
